Dideoxyinosine
[CAS# 69655-05-6]

Identification

• Classification: API >> Synthetic anti-infective drugs >> Antiviral drugs
• Name: Dideoxyinosine
• Synonyms: 2',3'-Dideoxyinosine
• Protein Sequence: N
• Molecular Formula: C₁₀H₁₂N₄O₃
• Molecular Weight: 236.23
• CAS Registry Number: 69655-05-6
• EC Number: 614-994-4
• SMILES: C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O

Properties

• Solubility: 48 mg/mL (DMSO), <1 mg/mL (Water) (Expl.)
• Density: 1.8±0.1 g/cm³, Calc.^*
• Melting point: 193 ºC (Expl.)
• Index of Refraction: 1.798, Calc.^*
• Boiling Point: 644.5±45.0 ºC (760 mmHg), Calc.^*
• Flash Point: 343.6±28.7 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07;GHS08 Danger
• Hazard Statements: H315-H319-H335-H341-H372
• Precautionary Statements: P203-P260-P261-P264-P264+P265-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P318-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Germ cell mutagenicity	Muta.	2	H341
Specific target organ toxicity - repeated exposure	STOT RE	1	H372

Discovory and Applicatios

Dideoxyinosine (DDI), also known as 2',3'-dideoxyinosine, is a purine nucleoside analog used primarily in the treatment of human immunodeficiency virus (HIV) infections. It is an important member of a class of antiretroviral drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). The discovery and development of DDI provided a significant advancement in the management of HIV/AIDS, especially during the early days of the epidemic.

DDI was first synthesized in the 1980s as part of efforts to develop compounds that could inhibit the action of reverse transcriptase, an enzyme that is crucial for the replication of HIV. The structure of DDI closely resembles that of deoxyinosine, a natural nucleoside, but with a key modification: the absence of a 3'-hydroxy group on the sugar ring. This alteration prevents the enzyme from adding additional nucleotides during viral replication, effectively halting the process. The mechanism of action is similar to that of other NRTIs, which include drugs like zidovudine (AZT) and lamivudine (3TC).

DDI was granted approval by the U.S. Food and Drug Administration (FDA) in 1991 for use in HIV treatment. It was initially marketed under the brand name Videx and was available as both oral capsules and powder for oral suspension. DDI works by incorporating into the viral DNA chain during replication, causing chain termination due to the lack of a 3'-hydroxy group that is necessary for further elongation of the DNA strand.

In terms of clinical application, DDI was used as part of combination antiretroviral therapy (cART), a standard approach in HIV treatment that involves using multiple drugs with different mechanisms of action to reduce the risk of viral resistance. By inhibiting reverse transcriptase, DDI helps to lower the viral load in patients and improve immune system function, as measured by CD4 cell count.

Although effective, DDI is associated with several side effects, including gastrointestinal issues, peripheral neuropathy, and pancreatitis. The drug was eventually superseded by other NRTIs that are better tolerated and have fewer side effects. However, it remains a key part of HIV treatment history and continues to be studied for its effects in various treatment regimens.

DDI's discovery and application represent a milestone in the fight against HIV/AIDS. The drug demonstrated the potential of nucleoside analogs in treating viral infections, paving the way for the development of additional antiretroviral therapies that have significantly improved the prognosis of HIV-infected individuals.